CD44 expression in colorectal cancer

Annals of the New York Academy of Sciences

Volumn 859, Issue , 1998, Pages 304-306

  Weg Remers, Susanne ^a,b   Schüder, Gerhard ^a   Zeitz, Martin ^a   Stallmach, Andreas ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD44V ANTIGEN; HERMES ANTIGEN; TUMOR MARKER;

ANTIGEN EXPRESSION; CANCER SCREENING; COLORECTAL CANCER; CONFERENCE PAPER; ENDOSCOPY; HIGH RISK PATIENT; HUMAN; SIGNAL TRANSDUCTION;

EID: 0032406459     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb11151.x     Document Type: Conference Paper

References (10)

1. 1. SCREATON, G. R., M. V. BELL, D. G. JACKSON, F. B. CORNELIS, U. GERTH & J. I. Bell. 1992. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. Natl. Acad. Sci. USA 89: 12160-12164.
2. 2. SHERMAN, L., J. SLEEMAN, P. Dall, A. Hekele, J. Moll, H. Ponta & P. Herrlich. 1996. The CD44 proteins in embryonic development and in cancer. Curr. Top. Microbiol. Immunol. 213: 249-269.
3. 3. TAHER, T. E. I., L. SMIT, A. W. GRIFFIOEN, E. J. M. SCHILDER-TOL, J. BORST & S. T. PALS. 1996. Signaling through CD44 is mediated by tyrosine kinases. J. Biol. Chem. 271: 2863-2867.
4. 4. GUNTHERT, U., M. HOFFMANN, W. RUDY, S. REBER, M. ZOLLER, I. HAUSSMANN, S. MATZKU, A. WENZEL, H. PONTA & P. HERRLICH. 1991. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13-24.
5. 5. FINKE, L. H., H. J. TERPE, C. ZORB, W. HAENSCH & P. M. SCHLAG. 1995. Colorectal cancer prognosis and expression of exon-v6-containing CD44-proteins. Lancet 345: 583.
6. 6. HOFMANN, M., W. RUDY, U. GUNTHERT, S. G. ZIMMER, V. ZAWADZKI, M. ZOLLER, R. B. LICHTNER, P. HERRLICH & H. PONTA. 1993. A link between ras and metastatic behavior of tumor cells: Ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res. 53: 1516-1521.
7. 7. WEG-REMERS, S., U. HILDEBRAND, G. FEIFEL, C. MOSER, M. ZEITZ & A. STALLMACH. 1998. Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6. Am. J. Gastroenterol. 93: 790-794.
8. 8. GUO, Y. J., G. LIU, X. WANG, D. JIN, M. WU, J. MA & M. S. SY. 1994. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res. 54: 422-426.
9. 9. MULDER, J. W. R., P. M. KRUYT, M. SEWNATH, J. OOSTING, C. A. SELDENRIJK, W. F. WEIDEMA, G. J. A. OFFERHAUS & S. T. PALS. 1994. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 344: 1470-1471.
10. 10. YAMAGUCHI, A., T. URANO, T. GOL, M. SAITO, K. TAKEUCHI, K. HIROSE, G. NAKAFAWARA, H. SHIKU & K. FURUKAWA. 1996. Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J. Clin. Oncol. 14: 1122-1127.